Eagle Pharmaceuticals, Inc. Reports First Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
Eagle Pharmaceuticals (EGRX) Reports In-Line Q1 EPS
May 8, 2017 6:54 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.42, in-line with the analyst estimate of $1.42. Revenue for the quarter came in at $76.8 million versus the consensus estimate of $70.37 million.
For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.
... More